COMMUNIQUÉS West-GlobeNewswire
-
AbCellera Announces Expanded Research Collaboration with Teva
13/06/2017 - 15:00 -
RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S.
13/06/2017 - 14:00 -
Novo Nordisk A/S - Share repurchase programme
13/06/2017 - 13:21 -
Midatech Pharma Plc: R&D manufacturing site visit for investors and analysts
13/06/2017 - 13:00 -
Summit Therapeutics plc : Notice of Results
13/06/2017 - 13:00 -
Acarix Receives First Commercial Order For CADScor®System For Early Detection Of Coronary Artery Disease From Danish Hospital
13/06/2017 - 11:00 -
Silmäasema Oyj: Managers' Transactions - Kaisa Vikkula
13/06/2017 - 10:00 -
Silmäasema Oyj: Managers' Transactions - Anu Kankkunen
13/06/2017 - 10:00 -
Silmäasema Oyj: Managers' Transactions - Torsti Sihvola
13/06/2017 - 10:00 -
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants
13/06/2017 - 09:00 -
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
13/06/2017 - 07:15 -
Biocartis Group NV: Disclosure of a transparency notification
13/06/2017 - 07:01 -
ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER
13/06/2017 - 07:00 -
argenx to Present at JMP Securities Life Sciences Conference
13/06/2017 - 07:00 -
Biocartis Group NV: Biocartis launches CE-marked IVD test for lung cancer
13/06/2017 - 07:00 -
TiGenix Launches Global Phase III Trial for Cx601
13/06/2017 - 07:00 -
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
12/06/2017 - 23:15 -
ProLynx présente PLX039, un système d'administration de médicament sous forme de microsphères d'hydrogel impliquant la prise mensuelle unique d'un agoniste de récepteur GLP 1
12/06/2017 - 21:12 -
Silmäasema Oyj: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act
12/06/2017 - 20:15
Pages